Amanda M. Koire

Amanda M. Koire

Auto-generated profile, based on publicly available information

Amanda M. Koire

Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA; Mary Horrigan Connors Center for Women's Health, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
RCRachel C. Conrad
Rachel C. Conrad
HHHyeouk “Chris” Hahm
Hyeouk “Chris” Hahm
AKAmanda Koire
Amanda Koire
SPStephanie Pinder-Amaker
Stephanie Pinder-Amaker
CLCindy H. Liu
Cindy H. Liu

3 September 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JMJitendra K. Meena
Jitendra K. Meena
JWJarey H. Wang
Jarey H. Wang
NNNicholas J. Neill
Nicholas J. Neill
DKDianne Keough
Dianne Keough
Nagireddy PutluriNagireddy Putluri
Nagireddy Putluri
TWThomas F. Westbrook
Thomas F. Westbrook
Upregulation of MYC is a hallmark of cancer, wherein MYC drives oncogenic gene expression and elevates total RNA synthesis across cancer cell transcriptomes. Although this transcriptional anabolism fuels cancer growth and survival, the consequences and metabolic stresses induced by excess cellular RNA are poorly understood. Herein, we discover that RNA degradation and downstream ribonucleotide catabolism is a novel mechanism of MYC-induced cancer cell death. Combining genetics and metabolomics, we find that MYC increases RNA decay through the cytoplasmic exosome, resulting in the accumulation of cytotoxic RNA catabolites and reactive oxygen species. Notably, tumor-derived exosome mutations abrogate MYC-induced cell death, suggesting excess RNA decay may be toxic to human cancers. In agreement, purine salvage acts as a compensatory pathway that mitigates MYC-induced ribonucleotide catabolism, and inhibitors of purine salvage impair MYC+ tumor progression. Together, these data suggest that MYC-induced RNA decay is an oncogenic stress that can be exploited therapeutically. Significance: MYC is the most common oncogenic driver of poor-prognosis cancers but has been recalcitrant to therapeutic inhibition. We discovered a new vulnerability in MYC+ cancer where MYC induces cell death through excess RNA decay. Therapeutics that exacerbate downstream ribonucleotide catabolism provide a therapeutically tractable approach to TNBC (Triple-negative Breast Cancer) and other MYC-driven cancers.

19 May 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
AKAmanda Koire
Amanda Koire
Panagiotis KatsonisPanagiotis Katsonis
Panagiotis Katsonis
YKYoung Won Kim
Young Won Kim
CBChristie Buchovecky
Christie Buchovecky
SWStephen J. Wilson
Stephen J. Wilson
OLOlivier Lichtarge
Olivier Lichtarge
An evolutionary action approach elucidates the genotype-phenotype relationship in autism spectrum disorder.

18 November 2015
Verified
Conference Paper
Open access
PDF file
AKAmanda Koire
Amanda Koire
Panagiotis KatsonisPanagiotis Katsonis
Panagiotis Katsonis
OLOlivier Lichtarge
Olivier Lichtarge
When seeking to reproduce results derived from whole-exome or genome sequencing data that could advance precision medicine, the time and expense required to produce a patient cohort make data repurposing an attractive option. The first step in repurposing is setting some quality baseline for the data so that conclusions are not spurious. This is difficult because there can be variations in quality from center to center, clinic to clinic and even patient to patient. Here, we assessed the quality of the whole-exome germline mutations of TCGA cancer patients using patterns of nucleotide substitution and negative selection against impactful mutations. We estimated the fraction of false positive variant calls for each exome with respect to two gold standard germline exomes, and found large variability in the quality of SNV calls between samples, cancer subtypes, and institutions. We then demonstrated how variant features, such as the average base quality for reads supporting an allele, can be used to identify sample-specific filtering parameters to optimize the removal of false positive calls. We concluded that while these germlines have many potential applications to precision medicine, users should assess the quality of the available exome data prior to use and perform additional filtering steps.

1 August 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AKAmanda Koire
Amanda Koire
MSMariella Suleiman
Mariella Suleiman
PTPolina Teslyar
Polina Teslyar
CLCindy H. Liu
Cindy H. Liu
In the US, 86% of women will become mothers and approximately 20% will experience a peripartum mood episode.1 Despite perinatal mental health accounting for substantial maternal mortality, 3 in 4 women do not receive treatment.2 One challenge for patients is finding psychiatric treatment. Nonpsychiatrist physicians have historically expressed a lack of training and confidence regarding mental health treatment of pregnant individuals, and many psychiatrists express similar hesitation. Meanwhile, long wait times for evaluation worsen depression and increase risk of self-harm ideation.3 Access to perinatal psychiatry subspecialists in academic centers is limited,4 yet the landscape of access in the community has not been well studied. This cross-sectional study identified and quantified state-level shortages in community-based perinatal psychiatry care.

26 May 2022 in Harvard Review of Psychiatry
Verified
Journal Article
Closed access
AKAmanda Koire
Amanda Koire
HJHadine Md Joffe
Hadine Md Joffe
RBRachel Buckley
Rachel Buckley
Learning objectives: After participating in this activity, learners should be better able to: • Outline the clinical recommendations for menopausal hormone treatment related to cognitive concerns • Debate and discuss the various research pieces on the use of menopausal hormone therapy cognitive decline, dysfunction, and dementia Menopause has been associated with subjective cognitive dysfunction and elevated rates of depression. While menopausal hormone therapy (MHT) is Food and Drug Administration–approved for the treatment of vasomotor symptoms related to menopause, a potential role for MHT in treating and preventing cognitive decline, dysfunction, and dementia has remained unclear and a topic of continued interest and debate across decades of research. Increasing numbers of patients are seeking help for subjective cognitive decline, and those with poorer mental health are substantially more likely to perceive themselves to be at high risk of developing dementia; thus, mental health professionals are likely to encounter such patients and may be asked to provide advice concerning MHT, cognition, and indications for MHT use. Here, we synthesize the neurobiological effects of MHT, make recommendations for its use in current clinical practice in the contexts of cognitive dysfunction associated with major depressive disorder, cognitive decline, and Alzheimer’s disease, and discuss the frontiers being explored by ongoing research on this topic. We conclude that MHT to improve cognitive functioning has only a few scenarios where it would be recommended and that particular caution may be warranted for carriers of the APOE ε4 allele.